Clinical Trial Detail

NCT ID NCT03131206
Title A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

thyroid cancer

non-small cell lung carcinoma

Therapies

Alectinib

Age Groups: adult senior

Additional content available in CKB BOOST